Cargando…
Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217302/ https://www.ncbi.nlm.nih.gov/pubmed/37232839 http://dx.doi.org/10.3390/curroncol30050381 |
| _version_ | 1785048503992451072 |
|---|---|
| author | Rayson, Daniel Gandhi, Sonal Joy, Anil A. Brezden-Masley, Christine Gelmon, Karen A. Sehdev, Sandeep Cescon, David Chia, Stephen |
| author_facet | Rayson, Daniel Gandhi, Sonal Joy, Anil A. Brezden-Masley, Christine Gelmon, Karen A. Sehdev, Sandeep Cescon, David Chia, Stephen |
| author_sort | Rayson, Daniel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10217302 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | MDPI |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102173022023-05-27 Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” Rayson, Daniel Gandhi, Sonal Joy, Anil A. Brezden-Masley, Christine Gelmon, Karen A. Sehdev, Sandeep Cescon, David Chia, Stephen Curr Oncol Reply MDPI 2023-05-16 /pmc/articles/PMC10217302/ /pubmed/37232839 http://dx.doi.org/10.3390/curroncol30050381 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Reply Rayson, Daniel Gandhi, Sonal Joy, Anil A. Brezden-Masley, Christine Gelmon, Karen A. Sehdev, Sandeep Cescon, David Chia, Stephen Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title_full | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title_fullStr | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title_full_unstemmed | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title_short | Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895” |
| title_sort | reply to trudeau, m.; fraser, b. the cadth pcodr expert review committee process explained. comment on “rayson et al. access to neoadjuvant pertuzumab for her2 positive breast cancer in canada: a dilemma increasingly difficult to explain. curr. oncol. 2022, 29, 9891–9895” |
| topic | Reply |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217302/ https://www.ncbi.nlm.nih.gov/pubmed/37232839 http://dx.doi.org/10.3390/curroncol30050381 |
| work_keys_str_mv | AT raysondaniel replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT gandhisonal replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT joyanila replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT brezdenmasleychristine replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT gelmonkarena replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT sehdevsandeep replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT cescondavid replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 AT chiastephen replytotrudeaumfraserbthecadthpcodrexpertreviewcommitteeprocessexplainedcommentonraysonetalaccesstoneoadjuvantpertuzumabforher2positivebreastcancerincanadaadilemmaincreasinglydifficulttoexplaincurroncol20222998919895 |